Gene targeting effects by topo i somerase inhibitors using plasma free DNA in patients with SCLC

2010 Fiscal Year Final Research Report

• Project/Area Number: 21790780
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Single-year Grants
• Research Field: Respiratory organ internal medicine
• Research Institution: Osaka City University
• Principal Investigator: KIMURA Tatsuo Osaka City University, 大学院・医学研究科, 病院講師 (50382049)
• Project Period (FY): 2009 – 2010
• Keywords: 小細胞肺癌 / トポイソメラーゼ阻害剤 / 血漿DNA / イリノテカン / エトポシド / ァムルビシン

Research Abstract

Lung cancer is the leading cause of cancer death, and approximately 15% of all lung cancer patients have small-cell lung cancer (SCLC). Although second-line chemotherapy can produce tumor regression, the prognosis is poor. Amrubicin hydrochloride (AMR) is a synthetic anthracycline anticancer agent and a potent topoisomerase II inhibitor. With its predictable and manageable toxicities, AMR is one of the most attractive agents for the treatment of chemotherapy- sensitive and -refractory relapsed SCLC. I reviewed the applicability of AMR therapy for patients with SCLC on Clinical Medicine Insights Oncology 2011. These clinical trials, including phase III studies, will clarify the status of AMR in the treatment of SCLC.

Research Products

• [Journal Article] Review of the Management of Relapsed Small-Cell Lung Cancer with Amrubicin Hydrochloride. (2011)
  • Author(s): Kimura T, Kudoh S, Hirata K.
  • Journal Title: Clinical Medicine Insights : Oncology 5 Pages: 23-34
  • Peer Reviewed
• [Journal Article] Soft Tissue Squamous Cell Carcinoma in Chest Wall with an Incomplete Border Sign (2011)
  • Author(s): Kimura T, Kudoh S, Tochino Y, Kodama T, Matsumura S, Hirata K
  • Journal Title: J Med Cases 2(1) Pages: 31-33
  • Peer Reviewed
• [Journal Article] Reaction of plasma hepatocyte growth factor levels in non-small cell lung cancer patients treated with EGFR-TKIs. (2010)
  • Author(s): Tanaka H, Kimura T, Kudoh S, Mitsuoka S, Watanabe T, Suzumura T, Tachibana K, Noguchi M, Yano S, Hirata K.
  • Journal Title: Int J Cancer. [Epub ahead of print] 掲載確定(Webではすでに掲載済み)
  • Peer Reviewed
• [Journal Article] Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG0401). (2010)
  • Author(s): Kaneda H, Okamoto I, Kimura T, et al.
  • Journal Title: J Thorac Oncol. 5 Pages: 105-109
  • Peer Reviewed
• [Journal Article] Phase II study of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer. (2009)
  • Author(s): Yoshimura N, Kudoh S, Kimura T, Mitsuoka S, Kyoh S, Tochino Y, Asai K, Kodama T, Ichimaru Y, Yana T, Hirata K
  • Journal Title: J Thorac Oncol. 4 Pages: 371-375
  • Peer Reviewed
• [Journal Article] Plasma concentration of amrubicinol in plateau phase in patients treated for 3 days with amrubicin is correlated with hematological toxicities. (2009)
  • Author(s): Kimura T, Kudoh S, Mitsuoka S, Yoshimura N, Tanaka H, Asai K, Kyoh S, Tochino Y, Umekawa K, Hirata K.
  • Journal Title: Anticancer Drugs. 20(6) Pages: 513-518
  • Peer Reviewed
• [Presentation] Reaction of plasma hepatocyte growth factor by administration EGFR-TKls in lung cancer patients. (2010)
  • Author(s): Tanaka H, Kimura T, Suzumura T, Umekawa K, Nagata M, Mitsuoka S, Kudoh S, Yano S, Hirata K.
  • Organizer: 35th ESMO Congress 2010.
  • Place of Presentation: ミラノ
  • Year and Date: 2010-10-01
• [Presentation] Comparison of adverse events of erlotinib with those of gefitinib in Japanese patients with NSCLC. (2010)
  • Author(s): Suzumura T, Kudoh S, Kimura T, Umakawa K, Tanaka H, Mitsuoka S, Yoshimura N, Hirata K.
  • Organizer: ASCO Annual '10Meeting
  • Place of Presentation: シカゴ
  • Year and Date: 2010-06-01
• [Presentation] Feasibility study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II-IIIA non-small cell lung cancer. (2010)
  • Author(s): Yoshimura N, Kudoh S, Mitsuoka S, Kimura T, Hirata K.
  • Organizer: ASCO Annual '10Meeting.
  • Place of Presentation: シカゴ
  • Year and Date: 2010-06-01
• [Presentation] 再発小細胞肺癌における治療抵抗性症例<refractory relapse>の検討 (2010)
  • Author(s): 梅川加奈子, 木村達郎, 井尻尚樹, 武田倫子, 小林大起, 白土直子, 鈴村倫弘, 渡辺徹也, 藤本寛樹, 田中秀典, 松村佐恵子, 児玉豊城, 一丸之寿, 光岡茂樹, 浅井一久, 姜成勲, 吉村成夫, 鴨井博, 金澤博, 工藤新三, 平田一人
  • Organizer: 第50回日本呼吸器学会学術講演会
  • Place of Presentation: 京都
  • Year and Date: 2010-04-01
• [Presentation] Plasma concentration of amrubicinol in gamma phase in patients treated for 3 days with amrubicin and hematological toxicities. (2009)
  • Author(s): Kimura T, Kudoh S, Mitsuoka S, Tanaka H, Kyoh S, Suzumura T, Yoshimura N, Asai K, Tochino Y, Hirata K.
  • Organizer: ASCO Annual '09Meeting
  • Place of Presentation: オーランド
  • Year and Date: 2009-05-01